On November 7, Arkuda Therapeutics announced the completion of a $44 million Series A round of financing, led by Atlas Venture and Pfizer Ventures, and Tekla Capital Management and BioInnovation Capital. The company will use the funds to promote its treatment of frontotemporal dementia (FTD) drugs through Phase I… Continue Reading Targeting granule protein precursors to prevent dementia, this company is spotlighted by Pfizer

  I. Introduction   Histamine was first discovered in the last century. It is the main medium for many biological reactions including allergic reactions. Some of these biological reactions are involved in the pathophysiological processes of common skin diseases. In theory, there are three ways to block the biological effects… Continue Reading Antihistamines for itch treatment

  Immunotherapy is considered to be the fourth pillar of cancer treatment (in parallel with surgery, radiotherapy, and chemotherapy), by enhancing the ability of the immune system to target and kill tumor cells, including: 1) Blocking antibodies to the inhibitory immune checkpoint pathway 2) Cell therapy based on dendritic cells… Continue Reading Nature: The next step in cancer immunotherapy is joint therapy. Eradication of cancer is not the ultimate goal.

  Lupus erythematosus (LE) is a typical autoimmune connective tissue disease and a disease-causing disease. One end of the spectrum is cutaneous lupus erythematosus (CLE), the lesion is mainly confined to the skin; the other end is systemic lupus erythematosus (SLE), in addition to skin damage, the lesion involves multiple… Continue Reading Pathogenesis of skin-type lupus erythematosus and analysis of 9 new treatments

  From the discovery of tubulin to the approval of vinblastine for anticancer treatment, it has been more than half a century. Microtubules play an extremely important role in cell division, and disruption of the formation of mitotic spindles affects all dividing cells. For cancer cells that proliferate faster than… Continue Reading The development of microtubule inhibitors – the big story of small molecules

  Opioids are usually the mainstay of perioperative and chronic pain, and even local pain treatment, but these drugs have many side effects, including nausea, irritations, itching, urinary retention, constipation, etc., and more serious tolerance. , addiction and the risk of overuse of death. Opioids are usually administered systemically, primarily… Continue Reading Tetrodotoxin is “tamed” and has a local analgesic effect for up to 3 days! Or an alternative to opioids

  The regulation of human blood glucose concentration is mainly achieved by the mutual restriction of insulin and glucagon at multiple levels. Among them, insulin produced by islet β cells is responsible for promoting blood glucose absorption and lowering blood glucose concentration. Islet beta cell destruction or dysfunction can lead… Continue Reading Nature’s paper: Treating diabetes with cell therapy is worth looking forward to

  Pancreatic cancer is one of the most malignant tumors. It is called “the king of cancer” because of its low survival rate and extremely short survival period. It is usually asymptomatic in the early stage and often spreads to the whole body when it is diagnosed. Pancreatic cancer is… Continue Reading Nature: The king of cancer also has weakness

  Metformin is the most widely used type 2 diabetes drug, and is known as a “magic medicine” because of its anti-cancer and anti-aging effects. Now, scientists from the University of Dundee in the UK have recently discovered that metformin can also reverse the thickening of harmful myocardial walls that… Continue Reading Metformin may reduce the risk of heart disease, the first clinical trial results in top journals

  Following the announcement on February 12 that the ASK1 inhibitor selonsertib (GS4997) missed the first-order endpoint in its first phase III clinical trial (STELLAR-4), Gilead announced on April 25 that selonsertib was in another STELLAR-3 study. The scheduled clinical endpoint of 48 weeks was not reached.   STELLAR-4 study… Continue Reading Gilead NASH new drug selonsertib second phase III clinical failure